Forest strives to positively impact the health and quality of life of patients through the development of innovative prescription drug therapies.
08.30.2010 - Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of Cariprazine for the Treatment of Bipolar Depression
07.22.2010 - Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KGaA Settle NAMENDA(R) Patent Litigation
07.20.2010 - Forest Laboratories, Inc. Reports First Quarter FY 2011 EPS of $0.39, Including $0.39 Per Share Charge Related to Settlement in Principle with US Department of Justice and $0.17 Per Share Charge for New Product Licensing Fee